ReviewSeminars in immunopathology2015
Gene expression profiling offers insights into the role of innate immune signaling in SSc.
Review in Seminars in immunopathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04630782 (Precision Medicine in Systemic Sclerosis Gastrointestinal Disease), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Precision Medicine in Systemic Sclerosis Gastrointestinal Disease: Evaluating Imaging and Stool Biomarkers for Differentiating Disease Stages and Treatment Responses
Who cites it
16 citing papers in PubMed, 25 citations in OpenAlex.
- Mycophenolate Mofetil Treatment of Systemic Sclerosis Reduces Myeloid Cell Numbers and Attenuates the Inflammatory Gene Signature in Skin.The Journal of investigative dermatology · 2018Trial
- Skin Gene Expression Profiles in Systemic Sclerosis: From Clinical Stratification to Precision Medicine.International journal of molecular sciences · 2023Review
- Clinical and laboratory characterization of patients with localized scleroderma and response to UVA-1 phototherapy: In vivo and in vitro skin models.Photodermatology, photoimmunology & photomedicine · 2022Article
- Systemic Sclerosis and Pulmonary Disease.Advances in experimental medicine and biology · 2021Article
- Analysis of gene expression profiles and protein-protein interaction networks in multiple tissues of systemic sclerosis.BMC medical genomics · 2019Article
- Macrophages in Systemic Sclerosis: Novel Insights and Therapeutic Implications.Current rheumatology reports · 2019Review
- Characterization of inflammatory cell infiltrate of scleroderma skin: B cells and skin score progression.Arthritis research & therapy · 2018Article
- Innate Immunity in Systemic Sclerosis Fibrosis: Recent Advances.Frontiers in immunology · 2018Review
- Black, White, and Gray: Macrophages in Skin Repair and Disease.Current pathobiology reports · 2017Article
- Toll-Like Receptor-4 Signaling Drives Persistent Fibroblast Activation and Prevents Fibrosis Resolution in Scleroderma.Advances in wound care · 2017Review
- A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis.Genome medicine · 2017Article
- Pathophysiological Mechanisms in Sclerosing Skin Diseases.Frontiers in medicine · 2017Review
- The Microbiome in Connective Tissue Diseases and Vasculitides: An Updated Narrative Review.Journal of immunology research · 2017Review
- Identification of Optimal Mouse Models of Systemic Sclerosis by Interspecies Comparative Genomics.Arthritis & rheumatology (Hoboken, N.J.) · 2016Article
- Tenascin-C drives persistence of organ fibrosis.Nature communications · 2016Article
- Molecular stratification and precision medicine in systemic sclerosis from genomic and proteomic data.Current opinion in rheumatology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Systemic sclerosis (SSc) is characterized by inflammation, vascular dysfunction, and ultimately fibrosis. Progress in understanding disease pathogenesis and developing effective disease treatments has been hampered by an incomplete understanding of SSc heterogeneity. To clarify this, we have used genomic approaches to identify distinct patient subsets based on gene expression patterns in SSc skin and other end-target organs. Here, we review what is known about the gene expression-based subsets in SSc, currently defined as the inflammatory, fibroproliferative, limited, and normal-like subsets. The inflammatory subset of patients is characterized by infiltrating immune cells that include T cells, macrophages, and possibly dendritic cells, although little is known about the mediators these cells secrete and the pathways that govern cell activation. Prior studies have suggested a role for pathogens as a trigger of immune responses in SSc, and recent data have identified viral and mycobiome components as potential environmental triggers. We present a model based on analyses of gene expression data and a review of the literature, which suggests that the gene expression subsets observed in patients possibly represent distinct, interconnected molecular states of disease, to which an innate immune response is central that results in the generation of clinical disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.